Catalyst Pharmaceutical Partners: (NASD: CPRX)
$0.88
-0.02 (-1.70%)
Volume 255,208
May 15 03:44 PM ET
Zacks Rank: 1-Strong Buy 
| #1 |
Overview Quote
Stock Activity
| Day Low - High | 0.87 - 0.93 |
| 52wk Low - High | 0.37 - 2.27 |
| Previous Close | 0.90 |
| Avg. Volume | 1,728,767 |
| Industry | MED-DRUGS |
| Market Cap | 37.08 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.92 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.28 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
1 |
Zacks Recommendation
|
Outperform |
Zacks Industry Rank
|
86 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.28 |
| Current Quarter Estimate | -0.07 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 05-15-2013 |
| EPS Last Year | -0.14 |
| Expected Earnings Growth | NA |
Company Description
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (03/2013) |
Next Qtr (06/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.07 | -0.08 | -0.28 | -0.23 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | -0.07 | -0.08 | -0.28 | -0.23 |
| High Estimate | -0.07 | -0.08 | -0.28 | NA |
| Year Ago EPS | -0.04 | -0.01 | -0.18 | -0.28 |
| EPS Growth | -75.00% | -700.00% | -55.56% | 17.86% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CATALYST PHARMA | CPRX | 0.90 | |
|
| JAZZ PHARMACEUT | JAZZ | 59.00 | |
|
| SALIX PHARM-LTD | SLXP | 59.29 | |
|
| SANTARUS INC | SNTS | 21.02 | |
|
| USANA HLTH SCI | USNA | 60.62 | |
|
| BIOCRYST PHARMA | BCRX | 1.81 | |
|
| CELL THERAPEUT | CTIC | 1.19 | |
|
| CUBIST PHARM | CBST | 48.77 | |
|
| ELAN CP PLC ADR | ELN | 11.45 | |
|
| INFINITY PHARMA | INFI | 32.98 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
FDA Accepts Merck BLA
May 15, 2013
Merck KGaA Posts Higher Y/Y Earnings
May 15, 2013
Dr. Reddy's Earnings Increase Y/Y
May 15, 2013
Forest-Trevena Ink Deal
May 14, 2013
Jazz Pharma Posts Higher Y/Y Earnings
May 14, 2013
Salix Beats on Earnings
May 14, 2013
Narrower-than-Expected Loss at Supernus
May 14, 2013
Glaxo/THRX's Breo Ellipta Gets FDA Nod
May 13, 2013
Financials
| EPS TTM | -0.14 |
| Sales | 0 |
| Net Income | -4 |
| Price/Earnings | NA |
| Price/Book | 2.54 |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
Catalyst Pharmaceutical PartnerCorporate Event Announcement Notice - Wall Street Horizon
May 14, 2013
Catalyst Pharmaceutical PartnerCorporate Event Announcement Notice - Wall Street Horizon
May 13, 2013
Catalyst Pharmaceutical PartnerCorporate Event Announcement Notice - Wall Street Horizon
May 10, 2013
Catalyst Pharmaceutical PartnerCorporate Event Announcement Notice - Wall Street Horizon
May 3, 2013
Catalyst Pharmaceutical PartnerCorporate Event Announcement Notice - Wall Street Horizon
May 2, 2013
Partial Seizure - Pipeline Review, H1 2013 - M2
May 2, 2013
MOO, HAO, HOMB, MXI, PYZ, CPRX Are Seasonally Ripe To Go Down In the Next Five Weeks - M2
Apr 25, 2013
Market Maker Surveillance Report. WCRX, PWER, S, CPRX, MJNA, ZNGA, Highest Net Sell Volume and Negative Price Friction For Tuesday, April 23rd 2013 - M2
Apr 24, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 2 |
| Average Target Price | 2.13 |
| Industry Rank by ABR | 86 out of 265 |
| Rank in Industry | 1 out of 91 |
